T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)
Daniel Castellano,Ignacio Duran,Alejo Rodriguez-Vida,Simon J. Crabb,M.S. van der Heijden,A. Font Pous,Gwenaelle Gravis,U. Anido Herranz,Andrew Protheroe,Alain Ravaud,Denis Maillet,M.J. Méndez-Vidal,Cristina Suarez,Anja Lorch,Cora N. Sternberg,Mark Linch,Shah-Jalal Sarker,J. Notta,Kelly Mousa,Thomas Powles +19 more
Journal ArticleDOI
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
Yohann Loriot,Thomas Powles,Miguel Angel Climent Duran,Srikala S. Sridhar,Joaquim Bellmunt,Daniel P. Petrylak,Jing Wang,Nuno Costa,Robert J Laliberte,Alessandra di Pietro,Petros Grivas,Cora N. Sternberg +11 more
TL;DR: Avelumab 1L maintenance is approved in the United States for patients with advanced UC that has not progressed with 1L platinum-containing chemotherapy based on significantly prolong...
Journal ArticleDOI
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
Yasmin Abu-Ghanem,Johannes V. Van Thienen,Christian U. Blank,Maureen J.B. Aarts,Michael Jewett,Igle J. de Jong,Jean-Baptiste Lattouf,Harm H.E. van Melick,Lori Wood,Peter F.A. Mulders,Sylvie Rottey,John Wagstaff,Patricia J. Zondervan,Thomas Powles,Anouk Neven,Laurence Collette,Bertrand Tombal,Bertrand Tombal,John B. A. G. Haanen,Axel Bex,Axel Bex +20 more
TL;DR: Sunitinib exposure in the immediate surgery or surgery after Sunitiniband Malate in treating patients with metastatic kidney cancer (SURTIME) trial was associated with the overall survival (OS) benefit observed in the deferred CN arm as discussed by the authors.
Journal ArticleDOI
Treatment patterns and outcomes in “real world” patients (pts) with metastatic urothelial cancer (UC).
Matthew D. Galsky,Simon Chowdhury,Joaquim Bellmunt,Yu-Ning Wong,Federica Recine,Sumanta K. Pal,Erin Moshier,Sylvain Ladoire,Ugo De Giorgi,Evan Y. Yu,Guenter Niegisch,Simon J. Crabb,Mabel A Mardones,Andrea Necchi,Ali Reza Golshayan,Aristotelis Bamias,Roy Mano,Lauren C. Harshman,Thomas Powles,Jonathan E. Rosenberg +19 more
TL;DR: An international retrospective cohort study to explore patterns of care/outcomes in “real world” pts with metastatic UC and found that only 758 received 1st-line chemotherapy for metastaticUC.